本文選題：阿帕 + 甲磺酸��； 參考：《實(shí)用醫(yī)學(xué)雜志》2017年22期

【摘要】：正晚期肺癌的預(yù)后差,在靶向治療及化療失敗后并沒(méi)有很有效的治療選擇~([1-2])。甲磺酸阿帕替尼是我國(guó)自主開(kāi)發(fā)的一種針對(duì)VEGFR2的小分子靶向藥物,在胃癌及乳腺癌中已見(jiàn)到明顯療效~([3-4])。在非小細(xì)胞肺癌中,國(guó)內(nèi)也有報(bào)道,顯示了一定的療效~([5])。本研究收集了本院2014年12月到2017年1月間經(jīng)甲磺酸阿帕替尼治療的晚期肺癌患者31例,觀察了其在不同肺癌類(lèi)型中的近期療效、不良反應(yīng),同時(shí)
[Abstract]:The prognosis of advanced lung cancer is poor and there is no effective treatment choice ([1-2]) after the failure of targeted therapy and chemotherapy. Apatinib mesylate is a small molecular targeted drug for VEGFR2 in China. It has been shown to be effective in gastric cancer and breast cancer ([3-4]). In non-small cell lung cancer (NSCLC), there are also reports in China, showing a certain curative effect ([5]). This study collected 31 patients with advanced lung cancer treated with Apatinib mesylate from December 2014 to January 2017, and observed their short-term efficacy, adverse reactions and adverse reactions in different types of lung cancer.
【作者單位】： 江蘇省連云港市第二人民醫(yī)院腫瘤化療科;
【分類(lèi)號(hào)】：R734.2
，

本文編號(hào)：1883024